Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Early specialised palliative care: interventions, symptoms, problems

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

BACKGROUND: Metformin has been shown to have both neuroprotective and neurodegenerative effects. The aim of this study was to investigate the effect of metformin in combination with insulin on cardiovascular autonomic neuropathy (CAN) and distal peripheral neuropathy (DPN) in individuals with type 2 diabetes (T2DM).

METHODS: The study is a sub-study of the CIMT trial, a randomized placebo-controlled trial with a 2 × 3 factorial design, where 412 patients with T2DM were randomized to 18 months of metformin or placebo in addition to open-labelled insulin. Outcomes were measures of CAN: Changes in heart rate response to deep breathing (beat-to-beat), orthostatic blood pressure (OBP) and heart rate and vibration detection threshold (VDT) as a marker DPN. Serum levels of vitamin B12 and methyl malonic acid (MMA) were analysed.

RESULTS: After 18 months early drop in OBP (30 s after standing) was increased in the metformin group compared to placebo: systolic blood pressure drop increased by 3.4 mmHg (95% CI 0.6; 6.2, p = 0.02) and diastolic blood pressure drop increased by 1.3 mmHg (95% CI 0.3; 2.6, p = 0.045) compared to placebo. Beat-to-beat variation decreased in the metformin group by 1.1 beats per minute (95% CI - 2.4; 0.2, p = 0.10). Metformin treatment did not affect VDT group difference - 0.33 V (95% CI - 1.99; 1.33, p = 0.39) or other outcomes. Changes in B12, MMA and HbA1c did not confound the associations.

CONCLUSIONS: Eighteen months of metformin treatment in combination with insulin compared with insulin alone increased early drop in OBP indicating an adverse effect of metformin on CAN independent of vitamin B12, MMA HbA1c. Trial registration The protocol was approved by the Regional Committee on Biomedical Research Ethics (H-D-2007-112), the Danish Medicines Agency and registered with ClinicalTrials.gov (NCT00657943).

Original languageEnglish
Article number150
JournalCardiovascular Diabetology
Volume19
Issue number1
Pages (from-to)150
ISSN1475-2840
DOIs
Publication statusPublished - 26 Sep 2020

    Research areas

  • Autonomic neuropathy, Cardiovascular autonomic neuropathy, Complications, Metformin, Orthostatic blood pressure recovery, Orthostatic hypotension, Peripheral neuropathy, Type 2 diabetes

ID: 60934285